英国艾滋病协会推荐B/F/TAF作为疫情期间唯一首选HIV治疗方案。图4. B/F/TAF在不同人群中的疗效[8-13] 参考文献: 1. Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic[J]. Lancet HIV. 2020 May; 7(5): e308-e309. 2. Guo W, Weng HL, Bai H, et al. Quick community survey on the impact of COVID-19 outbreak for the healthcare of people living with HIV[J]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Mar 30;41(5):663-667. 3. The cost of inaction: COVID-19-related service disruptions could cause hundreds of thousands of extra deaths from HIV. World Health Organization. https://mp.weixin.qq.com/s/682o89mcOoYhuw2GxZUjPA. 4. BHIVA guidance for the management of adults with HIV on antiretroviral treatment (ART) during the coronavirus pandemic. 2020. 5. Saag MS, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel[J]. JAMA. 2018 Jul 24;320(4):379-396. 6. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https://aidsinfo./contentfiles/lvguidelines/adultandadolescentgl.pdf 7. European AIDS Clinical Society. EACS Guidelines. https://www./files/2019_guidelines-10.0_final.pdf 8. Gallant J, Lazzarin A, Mills A, et al. Bictegravir,emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a doubleblind, multicentre, phase 3, randomised controlled noninferiority trial [J]. Lancet, 2017, 390(10107): 2063-2072. 9. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490 ) : a randomised ,doubleblind,multicentre, phase 3, non-inferiority trial [J]. Lancet,2017, 390(10107): 2073-2082. 10. Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre,active-controlled, phase 3, non-inferiority trial [J].Lancet HIV, 2018, 5(7): e357-e65. 11. Daar ES, Dejesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine,and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised,open-label, multicentre, phase 3, non-inferiority trial [J]. Lancet HIV, 2018, 5(7): e347-e56. 12. Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women 13. Gaur AH, Rodriguez C, Mcgrath EJ, et al. Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results. 14. Tsiang M, Jones GS, Goldsmith J, et al.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile[J]. Antimicrob Agents Chemother,2016, 60(12): 7086-97. 声明:本内容仅针对中国医疗卫生专业人士,旨在向且仅向医疗卫生专业人士提供科学信息,用于个人学习和参考之用。如果您不是医疗卫生专业人士,请勿参与或传播。 |
|